210 related articles for article (PubMed ID: 38398362)
1. VEXAS and Myelodysplastic Syndrome: An Interdisciplinary Challenge.
Kreutzinger V; Pankow A; Boyadzhieva Z; Schneider U; Ziegeler K; Stephan LU; Kübke JC; Schröder S; Oberender C; le Coutre P; Stintzing S; Jelas I
J Clin Med; 2024 Feb; 13(4):. PubMed ID: 38398362
[TBL] [Abstract][Full Text] [Related]
2. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
Kataoka A; Mizumoto C; Kanda J; Iwasaki M; Sakurada M; Oka T; Fujimoto M; Yamamoto Y; Yamashita K; Nannya Y; Ogawa S; Takaori-Kondo A
Int J Hematol; 2023 Jun; 117(6):919-924. PubMed ID: 36641501
[TBL] [Abstract][Full Text] [Related]
3. Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome.
Patel N; Dulau-Florea A; Calvo KR
Semin Hematol; 2021 Oct; 58(4):204-211. PubMed ID: 34802541
[TBL] [Abstract][Full Text] [Related]
4. VEXAS syndrome.
Nakajima H; Kunimoto H
Int J Hematol; 2024 May; ():. PubMed ID: 38819628
[TBL] [Abstract][Full Text] [Related]
5. Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS.
van der Made CI; Potjewijd J; Hoogstins A; Willems HPJ; Kwakernaak AJ; de Sevaux RGL; van Daele PLA; Simons A; Heijstek M; Beck DB; Netea MG; van Paassen P; Elizabeth Hak A; van der Veken LT; van Gijn ME; Hoischen A; van de Veerdonk FL; Leavis HL; Rutgers A
J Allergy Clin Immunol; 2022 Jan; 149(1):432-439.e4. PubMed ID: 34048852
[TBL] [Abstract][Full Text] [Related]
6. Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) with prominent supraglottic larynx involvement: a case-based review.
Guerrero-Bermúdez CA; Cardona-Cardona AF; Ariza-Parra EJ; Arostegui JI; Mensa-Vilaro A; Yague J; Vásquez G; Muñoz-Vahos CH
Clin Rheumatol; 2022 Nov; 41(11):3565-3572. PubMed ID: 35986821
[TBL] [Abstract][Full Text] [Related]
7. VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder.
Huang H; Zhang W; Cai W; Liu J; Wang H; Qin T; Xu Z; Li B; Qu S; Pan L; Huang G; Gale RP; Xiao Z
Exp Hematol Oncol; 2021 Mar; 10(1):23. PubMed ID: 33741056
[TBL] [Abstract][Full Text] [Related]
8. VEXAS Syndrome: A Novelty in MDS Landscape.
Templé M; Kosmider O
Diagnostics (Basel); 2022 Jun; 12(7):. PubMed ID: 35885496
[TBL] [Abstract][Full Text] [Related]
9. Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.
Obiorah IE; Patel BA; Groarke EM; Wang W; Trick M; Ombrello AK; Ferrada MA; Wu Z; Gutierrez-Rodrigues F; Lotter J; Wilson L; Hoffmann P; Cardona DO; Patel N; Dulau-Florea A; Kastner DL; Grayson PC; Beck DB; Young NS; Calvo KR
Blood Adv; 2021 Aug; 5(16):3203-3215. PubMed ID: 34427584
[TBL] [Abstract][Full Text] [Related]
10. Somatic Mutations in UBA1 Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS.
Ferrada MA; Sikora KA; Luo Y; Wells KV; Patel B; Groarke EM; Ospina Cardona D; Rominger E; Hoffmann P; Le MT; Deng Z; Quinn KA; Rose E; Tsai WL; Wigerblad G; Goodspeed W; Jones A; Wilson L; Schnappauf O; Laird RS; Kim J; Allen C; Sirajuddin A; Chen M; Gadina M; Calvo KR; Kaplan MJ; Colbert RA; Aksentijevich I; Young NS; Savic S; Kastner DL; Ombrello AK; Beck DB; Grayson PC
Arthritis Rheumatol; 2021 Oct; 73(10):1886-1895. PubMed ID: 33779074
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease.
Lötscher F; Seitz L; Simeunovic H; Sarbu AC; Porret NA; Feldmeyer L; Borradori L; Bonadies N; Maurer B
Front Immunol; 2021; 12():800149. PubMed ID: 35126364
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics, disease trajectories and management of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome: a systematic review.
Kouranloo K; Dey M; Almutawa J; Myall N; Nune A
Rheumatol Int; 2024 Jul; 44(7):1219-1232. PubMed ID: 38129348
[TBL] [Abstract][Full Text] [Related]
13. Clinical and genetic features of Japanese cases of MDS associated with VEXAS syndrome.
Kunimoto H; Miura A; Maeda A; Tsuchida N; Uchiyama Y; Kunishita Y; Nakajima Y; Takase-Minegishi K; Yoshimi R; Miyazaki T; Hagihara M; Yamazaki E; Kirino Y; Matsumoto N; Nakajima H
Int J Hematol; 2023 Oct; 118(4):494-502. PubMed ID: 37062784
[TBL] [Abstract][Full Text] [Related]
14. Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
Beck DB; Bodian DL; Shah V; Mirshahi UL; Kim J; Ding Y; Magaziner SJ; Strande NT; Cantor A; Haley JS; Cook A; Hill W; Schwartz AL; Grayson PC; Ferrada MA; Kastner DL; Carey DJ; Stewart DR
JAMA; 2023 Jan; 329(4):318-324. PubMed ID: 36692560
[TBL] [Abstract][Full Text] [Related]
15. [Clinical and genetic features of MDS associated with VEXAS syndrome].
Kunimoto H
Rinsho Ketsueki; 2024; 65(4):255-264. PubMed ID: 38684436
[TBL] [Abstract][Full Text] [Related]
16. Looking beyond VEXAS: Coexistence of undifferentiated systemic autoinflammatory disease and myelodysplastic syndrome.
Oganesyan A; Hakobyan Y; Terrier B; Georgin-Lavialle S; Mekinian A
Semin Hematol; 2021 Oct; 58(4):247-253. PubMed ID: 34802547
[TBL] [Abstract][Full Text] [Related]
17. VEXAS Syndrome-Review.
Zhang Y; Dong X; Wang H
Glob Med Genet; 2023 Sep; 10(3):133-143. PubMed ID: 37501758
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome.
Matsumoto H; Fujita Y; Fukatsu M; Ikezoe T; Yokose K; Asano T; Tsuchida N; Maeda A; Yoshida S; Hashimoto H; Temmoku J; Matsuoka N; Yashiro-Furuya M; Sato S; Murakami M; Sato H; Sakuma C; Kawashima K; Shakespear N; Uchiyama Y; Watanabe H; Kirino Y; Matsumoto N; Migita K
Front Immunol; 2022; 13():897722. PubMed ID: 35757758
[TBL] [Abstract][Full Text] [Related]
19. VEXAS syndrome: A review of cutaneous findings and treatments in an emerging autoinflammatory disease.
Saad AJ; Patil MK; Cruz N; Lam CS; O'Brien C; Nambudiri VE
Exp Dermatol; 2024 Mar; 33(3):e15050. PubMed ID: 38469984
[TBL] [Abstract][Full Text] [Related]
20. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry.
Comont T; Heiblig M; Rivière E; Terriou L; Rossignol J; Bouscary D; Rieu V; Le Guenno G; Mathian A; Aouba A; Vinit J; Dion J; Kosmider O; Terrier B; Georgin-Lavialle S; Fenaux P; Mekinian A;
Br J Haematol; 2022 Feb; 196(4):969-974. PubMed ID: 34651299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
